DaeWoong Pharmaceutical Announces Positive Safety Review for Bersiporocin
DaeWoong Pharmaceutical announced that its idiopathic pulmonary fibrosis (IPF) drug candidate, Bersiporocin, received a recommendation to continue its global Phase 2 clinical trial.
The third Independent Data Monitoring Committee (IDMC) review confirmed the safety of Bersiporocin, with no significant safety concerns found in the interim data from 89 enrolled patients.
- 94 patients enrolled out of 102 planned across Korea and the U.S.
- The study is progressing as planned, with approximately 92% of the target population enrolled.
The IDMC conducted an in-depth evaluation of interim safety data and found no significant safety concerns that would impact the trial's continuation.
Author's summary: DaeWoong Pharmaceutical's Bersiporocin continues global Phase 2 trial.
More News
- One UI 8 update rolls out for Samsung Galaxy M55s and F55
- Syngene International announces plans to add bioconjugation suite for end-to-end Antibody-Drug Conjugates Development
- Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project Front - FNArena.com
- Protecting Your Loved Ones: Estate Law Attorneys in Woodbury, NJ You Can Trust | NorthPennNow
- State begins distributing disaster aid to residents of Western Alaska, federal aid also approved
- NGS Streamlines Biomarker Testing in Solid Tumors | Oncology Nursing News
- GSK Agrees to $357 Million Exclusive License Agreement for Syndivia’s AntiBody-Drug Conjugate | PharmExec
- Man Utd Failed With £50 Million Mbeumo Alternative
- Switzerland To Change Designs
- MCU: Jeremy Allen White Responds to Popular X-Men Fan Casting